Biologic Agents As Biochemical Modulators: Pharmacologic Basis for the Interaction of Cytotoxic Chemotherapeutic Drugs and Interferon

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1994 Jan 1

PMID 7527304

Authors

S Wadler

E L Schwartz

Affiliations

Soon will be listed here.

Abstract

Biochemical modulation of cytotoxic cancer chemotherapeutic agents is one means of enhancing the activity and selectivity of antitumor drugs. Traditionally this approach has utilized detailed information regarding a particular enzymatic reaction or biochemical pathway to develop potential modulating agents. In contrast, the reported clinical therapeutic activity of IFN in combination with cytotoxic agents has prompted a reexamination of the biochemical actions of the cytokine. Interferon elicits a number of cellular actions that might contribute to its pharmacologic activity, including both direct antitumor effects and host-mediated actions. The best understood are those related to the cytotoxicity of the fluoropyrimidine antimetabolites and include enzymatic reactions involved in fluoropyrimidine metabolic activation, catabolism, and interaction with its target enzyme. However, even in this instance, a mechanistic association of a specific pharmacologic action with therapeutic activity remains to be determined. These studies demonstrate that cytokines and other biologic agents may exert specific biochemical modulations that augment (or potentially attenuate) the activity of the cytotoxic chemotherapeutic agents.

References

White C, Sondheimer H, Crouch E, Wilson H, Fan L . Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med. 1989; 320(18):1197-200. DOI: 10.1056/NEJM198905043201807. View

Kemeny N, Younes A, Seiter K, Kelsen D, Sammarco P, Adams L . Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer. 1990; 66(12):2470-5. DOI: 10.1002/1097-0142(19901215)66:12<2470::aid-cncr2820661205>3.0.co;2-y. View

Borden E, SIDKY Y, Hatcher J, Bryan G . Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta. Cancer Res. 1988; 48(9):2329-34. View

Wadler S, Fell S, Haynes H, Katz H, Rozenblit A, Kaleya R . Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. Cancer. 1993; 71(5):1726-30. DOI: 10.1002/1097-0142(19930301)71:5<1726::aid-cncr2820710504>3.0.co;2-m. View

Wadler S, Schwartz E . Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 1990; 50(12):3473-86. View

Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M . Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med. 1993; 329(22):1608-14. DOI: 10.1056/NEJM199311253292203. View

Divizia M, Baglioni C . Lack of correlation between thymidine kinase activity and the antiviral or antiproliferative response to interferon. Virology. 1984; 133(1):216-9. DOI: 10.1016/0042-6822(84)90442-2. View

HOUGHTON J, Adkins D, Rahman A, Houghton P . Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells. Cancer Commun. 1991; 3(7):225-31. DOI: 10.3727/095535491820873236. View

Koromilas A, Roy S, Barber G, Katze M, Sonenberg N . Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science. 1992; 257(5077):1685-9. DOI: 10.1126/science.1382315. View

10.

Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M . Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science. 1993; 259(5097):971-4. DOI: 10.1126/science.8438157. View

11.

Balkwill F, Mowshowitz S, Seilman S, Moodie E, Griffin D, Fantes K . Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes. Cancer Res. 1984; 44(11):5249-55. View

12.

Sen G, Lengyel P . The interferon system. A bird's eye view of its biochemistry. J Biol Chem. 1992; 267(8):5017-20. View

13.

Shuai K, Stark G, Kerr I, Darnell Jr J . A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science. 1993; 261(5129):1744-6. DOI: 10.1126/science.7690989. View

14.

Fornasiero A, Daniele O, Ghiotto C, Aversa S, Morandi P, Fiorentino M . Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer. Tumori. 1990; 76(4):385-8. DOI: 10.1177/030089169007600416. View

15.

Tanaka M, Kimura K, Yoshida S . Inhibition of mammalian DNA polymerases by recombinant alpha-interferon and gamma-interferon. Cancer Res. 1987; 47(22):5971-4. View

16.

Smalley R, Andersen J, Hawkins M, Bhide V, Oconnell M, Oken M . Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med. 1992; 327(19):1336-41. DOI: 10.1056/NEJM199211053271902. View

17.

Lee M, Price D, Specht S, Stemmler N, Katoh A . Interferon modulation of 5-fluorouracil: use in neoadjuvant therapy inhibits experimental liver metastases in nude mice. Anticancer Drugs. 1992; 3(4):413-8. View

18.

Talpaz M, Chernajovsky Y, Wetzler M, Kantarjian H, Gutterman J, Kurzrock R . Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. Cancer Res. 1992; 52(5):1087-90. View

19.

Weber G . Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. Cancer Res. 1983; 43(8):3466-92. View

20.

Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y . Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell. 1988; 54(6):903-13. DOI: 10.1016/s0092-8674(88)91307-4. View